It found that only 11% of patients receiving Dex developed cerebral hyperperfusion, compared to 38% in a placebo group. Only 3% of patients went on to develop cerebral hyperperfusion syndrome, ...
Advancing two pivotal Phase 3 trials of BXCL501 for acute treatment of agitation associated with bipolar disorders, schizophrenia, and ...
Igalmi (dexmedetomidine) is the first drug to be approved for this use that is formulated as an tablet that dissolves under the tongue, and the first new treatment for agitation in patients with ...
BACKGROUND: Dexmedetomidine is an α 2-receptor agonist used for sedation in the intensive care unit (ICU). Although dexmedetomidine is labeled for sedation in critically ill patients at doses up ...
Objectives: Although generally effective for sedation during noninvasive procedures, dexmedetomidine as the sole agent has not been uniformly successful for invasive procedures. To overcome some ...
Gland Pharma beat muted expectations for Q2FY25. There was increased Ebitda (Earnings before interest, taxes, depreciation ...
Side effects are generally mild and include lethargy, vomiting, and increased appetite. Sileo (generic name: dexmedetomidine) is an FDA-approved gel that treats noise aversion in dogs. It is the first ...
Get detailed information on Dexmedetomidine, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated ...
Dexmedetomidine HCl in 0.9% NaCl; 4mcg/mL; soln for IV infusion. Precedex (dexmedetomidine hydrochloride) injection 200 mcg/2 mL (100 mcg/mL) is clear and colorless. The strength is based on the ...
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
In six days, there were 35 reported drug overdoses in Waterloo region, prompting an alert from the Waterloo Region Integrated ...
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...